Clinical Trial Update: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating acalabrutinib in combination with DA-EPOCH-R or R-CHOP for patients with untreated diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | Status: RECRUITING